ATE92531T1 - Rekombinante herpes simplex-viren, vakzine und verfahren. - Google Patents

Rekombinante herpes simplex-viren, vakzine und verfahren.

Info

Publication number
ATE92531T1
ATE92531T1 AT87303512T AT87303512T ATE92531T1 AT E92531 T1 ATE92531 T1 AT E92531T1 AT 87303512 T AT87303512 T AT 87303512T AT 87303512 T AT87303512 T AT 87303512T AT E92531 T1 ATE92531 T1 AT E92531T1
Authority
AT
Austria
Prior art keywords
vaccines
methods
hsv
viruses
herpes simplex
Prior art date
Application number
AT87303512T
Other languages
English (en)
Inventor
Bernard Roizman
Original Assignee
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp filed Critical Arch Dev Corp
Application granted granted Critical
Publication of ATE92531T1 publication Critical patent/ATE92531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT87303512T 1986-04-25 1987-04-22 Rekombinante herpes simplex-viren, vakzine und verfahren. ATE92531T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/856,052 US4859587A (en) 1984-06-04 1986-04-25 Recombinant herpes simplex viruses, vaccines and methods
EP87303512A EP0243155B1 (de) 1986-04-25 1987-04-22 Rekombinante Herpes simplex-Viren, Vakzine und Verfahren

Publications (1)

Publication Number Publication Date
ATE92531T1 true ATE92531T1 (de) 1993-08-15

Family

ID=25322756

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87303512T ATE92531T1 (de) 1986-04-25 1987-04-22 Rekombinante herpes simplex-viren, vakzine und verfahren.

Country Status (9)

Country Link
US (1) US4859587A (de)
EP (1) EP0243155B1 (de)
JP (1) JPH084497B2 (de)
AT (1) ATE92531T1 (de)
AU (1) AU585126B2 (de)
CA (1) CA1305081C (de)
DE (1) DE3786824T2 (de)
ES (1) ES2059370T3 (de)
ZA (1) ZA87818B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5965138A (en) * 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
IE61575B1 (en) * 1987-05-04 1994-11-16 Merck & Co Inc A stable lyophilized live herpes virus vaccine
US5633152A (en) * 1988-06-24 1997-05-27 Carnegie Institution Of Washington Method of controlling viral growth
GB8918616D0 (en) * 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
EP0431668B1 (de) * 1989-12-04 1995-02-15 Akzo Nobel N.V. Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor
EP0541692B1 (de) * 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 impfstoffe
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5849572A (en) * 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6193984B1 (en) 1992-02-03 2001-02-27 Cedars-Sinai Medical Center Pharmaceutical composition of herpes simplex virus typ-1 (HSV-1) glycoproteins
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
US5672349A (en) * 1992-02-03 1997-09-30 Cedars Sinai Medical Center Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US6022726A (en) * 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
ES2183811T3 (es) 1992-03-31 2003-04-01 Arch Dev Corp Tratamiento de enfermedades tumorigenas con un hsv modificado.
US6316243B1 (en) 1992-04-14 2001-11-13 Peter Palese Genetically engineered attenuated double-stranded RNA viruses
US6183753B1 (en) * 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
TW289731B (de) * 1992-07-09 1996-11-01 Akzo Nv
JP4044131B2 (ja) * 1992-07-31 2008-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ ヘルペスウイルスワクチン
US7223411B1 (en) 1992-07-31 2007-05-29 Dana-Farber Cancer Institute Herpesvirus replication defective mutants
WO1994014971A1 (en) * 1992-12-23 1994-07-07 Arch Development Corporation Synthetic herpes simplex virus promoters
JPH09504429A (ja) * 1993-10-12 1997-05-06 チロン ビアジーン，インコーポレイティド 組換えウイルスの保存方法
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2728795B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
KR100408817B1 (ko) * 1995-07-28 2004-02-25 주식회사 엘지생명과학 헤르페스심플렉스바이러스의당단백질을대량발현시키는동물세포주
US5834216A (en) * 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
DE69722608T2 (de) * 1996-01-25 2004-04-29 The University Court Of The University Of Glasgow, Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
DE69838483T2 (de) 1997-10-14 2008-07-03 Darwin Molecular Corp. Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
US6399354B1 (en) 1998-07-31 2002-06-04 President And Fellows Of Harvard College Replication-competent virus expressing a detectable fusion protein
DK2272859T3 (en) * 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
EP1141338A4 (de) * 1998-12-31 2002-09-25 Arch Dev Corp Rekombinantes herpes simplex virus zur behandlung von neoplastischen erkrankungen
DE60039730D1 (de) * 1999-02-05 2008-09-11 Arch Dev Corp Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
US6774119B1 (en) 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
CA2378519C (en) 1999-07-07 2011-01-25 Zymogenetics, Inc. Human cytokine receptor
HK1044799A1 (zh) 1999-09-30 2002-11-01 University Of Washington 免疫学上重要的单纯疱疹病毒抗原
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6516246B2 (en) * 2000-09-11 2003-02-04 Mimicking Man Manually, Inc. Method and system for determining native neurological dominant hemisphere
EP1356071B1 (de) 2000-11-28 2007-11-21 The University of Chicago Genetisch veränderter herpes virus für die behandlung von herz- und gefässerkrankungen
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
JP4519461B2 (ja) * 2001-07-31 2010-08-04 ユニヴァーシティ オブ ワシントン 免疫学的に重要な単純ヘルペスウイルス抗原およびそれを用いる方法
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
RU2225223C1 (ru) * 2002-06-14 2004-03-10 Закрытое акционерное общество Фирма "ВИТАФАРМА" Лиофилизированная антигерпетическая вакцина
DK1523582T3 (da) * 2002-07-18 2009-03-02 Univ Washington Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
WO2005014796A2 (en) 2003-08-08 2005-02-17 Invitrogen Corporation Methods and compositions for seamless cloning of nucleic acid molecules
US8304189B2 (en) 2003-12-01 2012-11-06 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
US7731952B2 (en) * 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2007016239A2 (en) * 2005-07-29 2007-02-08 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
WO2010115172A2 (en) 2009-04-03 2010-10-07 University Of Washington Antigenic peptide of hsv-2 and methods for using same
DK2751279T3 (da) 2011-08-31 2017-11-20 St Jude Children's Res Hospital Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse
AU2013252909B2 (en) 2012-04-24 2017-09-28 University Of Miami Perforin 2 defense against invasive and multidrug resistant pathogens
EP3054946A2 (de) 2013-10-09 2016-08-17 University Of Miami Perforin-2-aktivatoren und -inhibitoren als zielarzneistoffe für infektionskrankheiten und darmentzündungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074808A3 (de) * 1981-09-16 1984-07-04 University Patents, Inc. Rekombinantes Verfahren und Materialien
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4554159A (en) * 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8305323D0 (en) * 1983-02-25 1983-03-30 Baylor College Medicine Infectious bovine rhinotracheitis vaccine
EP0133063B1 (de) * 1983-06-23 1987-01-07 Stanley Dr. Person Immunologisch reaktive nicht-glycosilierte Aminosäureketten von Glycoprotein-B des Herpes-Virus Typ 1 und Typ 2
NL8303501A (nl) * 1983-10-12 1985-05-01 Centraal Diergeneeskundig Inst Deletiemutant van een herpesvirus en vaccin, dat dit virus bevat.
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
EP0256092B1 (de) * 1986-01-27 1998-04-08 Syntro Corporation Abgeschwächte herpesviren, herpesviren, die eine für aminosäuresequenzen kodierende fremd-dns enthalten, sowie impfstoffe, die diese enthalten

Also Published As

Publication number Publication date
ES2059370T3 (es) 1994-11-16
ZA87818B (en) 1987-12-30
CA1305081C (en) 1992-07-14
EP0243155A2 (de) 1987-10-28
EP0243155B1 (de) 1993-08-04
AU585126B2 (en) 1989-06-08
US4859587A (en) 1989-08-22
JPS62257385A (ja) 1987-11-09
JPH084497B2 (ja) 1996-01-24
AU6861487A (en) 1987-10-29
EP0243155A3 (en) 1989-07-26
DE3786824T2 (de) 1994-01-20
DE3786824D1 (de) 1993-09-09

Similar Documents

Publication Publication Date Title
ATE92531T1 (de) Rekombinante herpes simplex-viren, vakzine und verfahren.
PH25776A (en) Pseudorabies virus mutants incapable of producing glycoprotein x
EP0500917A4 (en) Recombinant herpes simplex viruses vaccines and methods
MX9700833A (es) Virus de herpes recombinante de pavo y usos del mismo.
AU6489986A (en) Thymidine kinase deletion mutants of bovine herpersvirus-1, vaccines against infectious bovine rhinotracheitis containing same and methods for the production and use of same
EP0232798A3 (de) Pseudorabies-Virus-Mutanten, diese enthaltende Vakzine, Verfahren zu deren Herstellung sowie Methoden für deren Anwendung
UA40571C2 (uk) Мутант коров'ячого вірусу герпесу типу 1 (bhv-1), композиція вакцини для вакцинації тварин для захисту їх від bhv-1, композиція вакцини для вакцинації тварин для захисту їх від патогена
GR3032767T3 (en) Equine herpes viruses (EHV) containing foreign DNA, process for their preparation and their use as vaccines.
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
AU4334193A (en) Infectious bovine rhinotracheitis virus mutants and vaccines
GR3007856T3 (de)
DK0606452T3 (da) Vektorvacciner fra rekombinant katteherpesvirus
ATE244308T1 (de) Rekombitante, equine herpesviren
NZ220645A (en) Modified varicella-zoster virus and its cultivation
EA200100720A1 (ru) Вирусная вакцина на основе делеционного вируса герпеса крупного рогатого скота типа 1 (bhv-1)
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time